AU2007265460A1 — Prolyl hydroxylase inhibitors and methods of use
Assigned to Akebia Therapeutics Inc · Expires 2008-01-03 · 18y expired
What this patent protects
The present disclosure relates to HIF-lα prolyl hydroxylase inhibitors, compositions which comprise the HIF-lα prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failur…
USPTO Abstract
The present disclosure relates to HIF-lα prolyl hydroxylase inhibitors, compositions which comprise the HIF-lα prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.